Alphatec Raises Annual EBITDA Guidance on Improved Operating Leverage

Key Facts

In a move reflecting the improving financial performance of med-tech firms, Alphatec reported strong results driven by a 15% revenue growth. According to reports, the company successfully improved its operating leverage, leading it to raise its adjusted EBITDA guidance to $140 million. Although net losses persist, the company achieved a significant milestone as free cash flow turned positive during the period.

These results come as the company maintained its annual sales guidance at $882 million, supported by robust growth in its EOS imaging technology and operational efficiencies. Per analyst data, the shift toward positive free cash flow is expected to alleviate concerns regarding the company's leverage, especially as the growth trajectory in the medical devices sector remains intact.

Operationally, markets are monitoring the company's ability to sustain this momentum to reach break-even levels in upcoming quarters. Looking at the economic calendar, investors are awaiting the US ISM Manufacturing PMI data in August 2026, which may provide insights into production costs and broader demand trends within the industrial and medical sectors.